Cell line · CVCL_2077
Papers44
1 to 20 of 44
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting tumor-selective membrane-associated PCNA enables selective antibody-drug conjugate therapy. | Oncoimmunology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugates. | Antib Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Stromal collagen IV expression and risk of breast cancer death in ductal carcinoma in situ. | BJC Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| AIstain: Enhancing microglial phagocytosis analysis through deep learning. | Cell Rep Methods | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PRODH2-Mediated Metabolism in the Bone Microenvironment Promotes Breast Cancer Metastasis. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing the Efficacy of CAR-T Cell Production Using BX795 and Rosuvastatin in a Serum-Free Medium. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| 177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities. | J Exp Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Computational pipeline predicting cell death suppressors as targets for cancer therapy. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Define Critical Parameters of Trastuzumab-Mediated ADCC Assays via Assay Optimization Processes, Focusing on the Impact of Cryopreserved Effector Cells on Assay Performance. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative -specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy. | Front Immunol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. | Mol Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors. | Mol Cancer Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer. | Mol Cancer Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. | bioRxiv | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2077/papers